Biosafety of mesoporous silica nanoparticles; towards clinical translation
Advanced Drug Delivery Reviews · 2023-10 · 201 · 115049
DOI: 10.1016/j.addr.2023.115049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-10. Verfasst von Araceli Lérida-Viso und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Mixta de Investigación en Nanomedicina y Sensores. Universitat Politècnica de València, IIS La Fe. Av. Fernando Abril Martorell, 106 Torre A 7…. Hauptthemen laut MEDLINE: Silicon Dioxide, Nanoparticles. Die Arbeit wurde bisher 290-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mesoporous silica nanoparticles (MSNs) have attracted the attention of chemists, who have developed numerous systems for the encapsulation of a plethora of molecules, allowing the use of mesoporous silica nanoparticles for biomedical applications. MSNs have been extensively studied for their use in nanomedicine, in applications such as drug delivery, diagnosis, and bioimaging, demonstrating significant in vivo efficacy in different preclinical models. Nevertheless, for the transition of MSNs into clinical trials, it is imperative to understand the characteristics that make MSNs effective and safe. The biosafety properties of MSNs in vivo are greatly influenced by their physicochemical characteristics such as particle shape, size, surface modification, and silica framework. In this review, we compile the most relevant and recent progress in the literature up to the present by analyzing the contributions on biodistribution, biodegradability, and clearance of MSNs. Furthermore, the ongoing clinical trials and the potential challenges related to the administration of silica materials for advanced therapeutics are discussed. This approach aims to provide a solid overview of the state-of-the-art in this field and to encourage the translation of MSNs to the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad Mixta de Investigación en Nanomedicina y Sensores. Universitat Politècnica de València, IIS La Fe. Av. Fernando Abril Martorell, 106 Torre A 7ª planta. 46026, Valencia, Spain; Instituto Interuniversitario de Inve…
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat Politècnica de València, Universitat de València. Camino de Vera, s/n. 46022, Valencia, Spain; Unidad…
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat Politècnica de València, Universitat de València. Camino de Vera, s/n. 46022, Valencia, Spain; CIBER d…
Zitieren
APA
Lérida-Viso, A., Estepa-Fernández, A., García-Fernández, A., Martí-Centelles, V., & Martínez-Máñez, R. (2023). Biosafety of mesoporous silica nanoparticles; towards clinical translation. Advanced Drug Delivery Reviews, 201, 115049. https://doi.org/10.1016/j.addr.2023.115049
Vancouver
Lérida-Viso A, Estepa-Fernández A, García-Fernández A, Martí-Centelles V, Martínez-Máñez R. Biosafety of mesoporous silica nanoparticles; towards clinical translation. Advanced Drug Delivery Reviews. 2023;201:115049. doi:10.1016/j.addr.2023.115049
BibTeX
@article{LridaViso2023,
author = {Lérida-Viso, Araceli and Estepa-Fernández, Alejandra and García-Fernández, Alba and Martí-Centelles, Vicente and Martínez-Máñez, Ramón},
title = {Biosafety of mesoporous silica nanoparticles; towards clinical translation},
journal = {Advanced Drug Delivery Reviews},
year = {2023},
volume = {201},
pages = {115049},
doi = {10.1016/j.addr.2023.115049}
}
EUVIMED